Assignee

AVIDITY BIOSCIENCES INC

US·51 granted patents·31 pending applications·470 citations·filing 2017–2025

Technology mixC12N80 A61K79 A61P75 C07K70 C12Y14 C07F9

Top patents by PatentIndex Score

82 records

0198US12064483B2Nucleic acid-polypeptide compositions and methods of inducing exon skippingAVIDITY BIOSCIENCES INC·Filed 2022·Granted Aug 20, 2024·19 cites·24 claims
0298US11446387B2Compositions and methods of treating muscle dystrophyAVIDITY BIOSCIENCES INC·Filed 2021·Granted Sep 20, 2022·8 cites·14 claims
0398US11400163B2Nucleic acid-polypeptide compositions and methods of inducing exon skippingAVIDITY BIOSCIENCES INC·Filed 2021·Granted Aug 2, 2022·26 cites·22 claims
0498US11311627B1Nucleic acid-polypeptide compositions and methods of inducing exon skippingAVIDITY BIOSCIENCES INC·Filed 2021·Granted Apr 26, 2022·28 cites·24 claims
0598US11253607B2Compositions and methods of treating muscle atrophy and myotonic dystrophyAVIDITY BIOSCIENCES INC·Filed 2020·Granted Feb 22, 2022·7 cites·23 claims
0698US11246941B2Compositions and methods of treating muscle atrophy and myotonic dystrophyAVIDITY BIOSCIENCES INC·Filed 2021·Granted Feb 15, 2022·7 cites·23 claims
0798US11179472B2Nucleic acid-polypeptide compositions and methods of inducing exon skippingAVIDITY BIOSCIENCES INC·Filed 2018·Granted Nov 23, 2021·35 cites·25 claims
0898US11028179B2Anti-transferrin receptor antibodies and uses thereofAVIDITY BIOSCIENCES INC·Filed 2020·Granted Jun 8, 2021·16 cites·20 claims
0998US10994020B2Nucleic acid-polypeptide compositions and methods of inducing exon skippingAVIDITY BIOSCIENCES INC·Filed 2018·Granted May 4, 2021·32 cites·24 claims
1098US10913800B2Anti-transferrin receptor antibodies and uses thereofAVIDITY BIOSCIENCES INC·Filed 2020·Granted Feb 9, 2021·19 cites·27 claims
1198US10881743B2Compositions and methods of treating muscle atrophy and myotonic dystrophyAVIDITY BIOSCIENCES INC·Filed 2019·Granted Jan 5, 2021·55 cites·16 claims
1298US10787519B2Nucleic acid-polypeptide compositions and uses thereofAVIDITY BIOSCIENCES INC·Filed 2018·Granted Sep 29, 2020·19 cites·17 claims
1398US10550188B2Nucleic acid-polypeptide compositions and uses thereofAVIDITY BIOSCIENCES INC·Filed 2018·Granted Feb 4, 2020·80 cites·13 claims
1497US11707532B2Compositions and methods of treating muscle dystrophyAVIDITY BIOSCIENCES INC·Filed 2022·Granted Jul 25, 2023·3 cites·14 claims
1597US11576980B2Compositions and methods of treating muscle atrophy and myotonic dystrophyAVIDITY BIOSCIENCES INC·Filed 2021·Granted Feb 14, 2023·6 cites·23 claims
1697US11555190B2Compositions and methods of treating Facioscapulohumeral muscular dystrophyAVIDITY BIOSCIENCES INC·Filed 2021·Granted Jan 17, 2023·15 cites·17 claims
1797US11525137B2Compositions and methods of treating Facioscapulohumeral muscular dystrophyAVIDITY BIOSCIENCES INC·Filed 2021·Granted Dec 13, 2022·13 cites·21 claims
1897US11497814B2Compositions and methods of treating muscle atrophy and myotonic dystrophyAVIDITY BIOSCIENCES INC·Filed 2021·Granted Nov 15, 2022·3 cites·30 claims
1997US10487149B2Nucleic acid-polypeptide compositions and uses thereofAVIDITY BIOSCIENCES INC·Filed 2018·Granted Nov 26, 2019·21 cites·18 claims
2096US12049629B2Compositions and methods of treating Facioscapulohumeral muscular dystrophyAVIDITY BIOSCIENCES INC·Filed 2022·Granted Jul 30, 2024·2 cites·22 claims
2196US11999955B2Compositions and methods of treating facioscapulohumeral muscular dystrophyAVIDITY BIOSCIENCES INC·Filed 2022·Granted Jun 4, 2024·2 cites·16 claims
2296US11912779B2Compositions and methods of treating facioscapulohumeral muscular dystrophyAVIDITY BIOSCIENCES INC·Filed 2022·Granted Feb 27, 2024·6 cites·17 claims
2396US11834510B2Anti-transferrin receptor antibodies and uses thereofAVIDITY BIOSCIENCES INC·Filed 2021·Granted Dec 5, 2023·4 cites·20 claims
2496US11583591B2Compositions and methods of treating muscle atrophy and myotonic dystrophyAVIDITY BIOSCIENCES INC·Filed 2021·Granted Feb 21, 2023·2 cites·14 claims
2596US11554176B2Compositions and methods of treating muscle atrophy and myotonic dystrophyAVIDITY BIOSCIENCES INC·Filed 2021·Granted Jan 17, 2023·2 cites·16 claims
2696US11110180B2Nucleic acid-polypeptide compositions and uses thereofAVIDITY BIOSCIENCES INC·Filed 2018·Granted Sep 7, 2021·19 cites·20 claims
2795US12427202B2Compositions and methods of treating muscle dystrophyAVIDITY BIOSCIENCES INC·Filed 2023·Granted Sep 30, 2025·1 cites·9 claims
2895US12157774B2Compositions and methods of treating facioscapulohumeral muscular dystrophyAVIDITY BIOSCIENCES INC·Filed 2024·Granted Dec 3, 2024·1 cites·5 claims
2995US12071485B2Compositions and methods of treating facioscapulohumeral muscular dystrophyAVIDITY BIOSCIENCES INC·Filed 2024·Granted Aug 27, 2024·2 cites·13 claims
3095US10800848B2Nucleic acid-polypeptide compositions and uses thereofAVIDITY BIOSCIENCES INC·Filed 2018·Granted Oct 13, 2020·7 cites·16 claims
3195US2026007766A1Compositions and methods of treating muscle atrophy and myotonic dystrophyAVIDITY BIOSCIENCES INC·Filed 2025·Application pending·0 cites
3294US12104156B2Compositions and methods of treating facioscapulohumeral muscular dystrophyAVIDITY BIOSCIENCES INC·Filed 2022·Granted Oct 1, 2024·1 cites·16 claims
3394US11872287B2Compositions and methods of treating muscle atrophy and myotonic dystrophyAVIDITY BIOSCIENCES INC·Filed 2022·Granted Jan 16, 2024·1 cites·17 claims
3493US12006499B2Una amidites and uses thereofAVIDITY BIOSCIENCES INC·Filed 2020·Granted Jun 11, 2024·2 cites·8 claims
3593US11364302B1Nucleic acid-polypeptide compositions and uses thereofAVIDITY BIOSCIENCES INC·Filed 2021·Granted Jun 21, 2022·2 cites·20 claims
3693US2026060996A1Nucleic acid-polypeptide compositions and methods of inducing exon skippingAVIDITY BIOSCIENCES INC·Filed 2025·Application pending·0 cites
3791US12529056B2Compositions and methods of treating facioscapulohumeral muscular dystrophyAVIDITY BIOSCIENCES INC·Filed 2024·Granted Jan 20, 2026·0 cites·29 claims
3891US2024358736A1Nucleic acid-polypeptide compositions and methods of inducing exon skippingAVIDITY BIOSCIENCES INC·Filed 2024·Application pending·0 cites
3989US12359202B2Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skippingAVIDITY BIOSCIENCES INC·Filed 2024·Granted Jul 15, 2025·1 cites·21 claims
4089US12071621B2Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skippingAVIDITY BIOSCIENCES INC·Filed 2023·Granted Aug 27, 2024·1 cites·21 claims
4189US2024287522A1Compositions and methods of treating facioscapulohumeral muscular dystrophyAVIDITY BIOSCIENCES INC·Filed 2024·Application pending·0 cites
4289US2025340880A1Compositions and methods of treating facioscapulohumeral muscular dystrophyAVIDITY BIOSCIENCES INC·Filed 2025·Application pending·0 cites
4388US12486328B2Compositions and methods of treating facioscapulohumeral muscular dystrophyAVIDITY BIOSCIENCES INC·Filed 2025·Granted Dec 2, 2025·0 cites·19 claims
4488US2024400707A1Compositions and methods of treating facioscapulohumeral muscular dystrophyAVIDITY BIOSCIENCES INC·Filed 2024·Application pending·0 cites
4587US2026014266A1Compositions and methods of treating muscle dystrophyAVIDITY BIOSCIENCES INC·Filed 2025·Application pending·0 cites
4687US2025381285A1Compositions and methods of treating muscle dystrophyAVIDITY BIOSCIENCES INC·Filed 2025·Application pending·0 cites
4786US12263224B2Compositions and methods of treating muscle atrophy and myotonic dystrophyAVIDITY BIOSCIENCES INC·Filed 2022·Granted Apr 1, 2025·0 cites·15 claims
4885US2023047754A1Compositions and methods of treating muscle atrophy and myotonic dystrophyAVIDITY BIOSCIENCES INC·Filed 2022·Application pending·0 cites
4984US11578090B2Nucleic acid-polypeptide compositions and uses thereofAVIDITY BIOSCIENCES INC·Filed 2020·Granted Feb 14, 2023·1 cites·1 claims
5084US2025381286A1Nucleic acid-polypeptide compositions and methods of inducing exon skippingAVIDITY BIOSCIENCES INC·Filed 2025·Application pending·0 cites

Showing the top 50 of 82 patent records by PatentIndex Score.

Join the waitlist — get patent alerts

Get an alert when AVIDITY BIOSCIENCES INC files or is granted a new patent.

We store only your email — no account needed. See our privacy policy.

Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →